Clinical Trials Logo

Filter by:
NCT ID: NCT05431868 Completed - Cataract Clinical Trials

Objective and Subjective Outcomes of a Trifocal IOL in Eyes With Different AL

Start date: January 1, 2019
Phase:
Study type: Observational

This prospective cohort study enrolled patients with implantation of a trifocal IOL. Only one eye of each patient was enrolled. Eyes were devided into three groups according the axial length (AL), including the short AL group, the control group and the long AL group. Manifest refraction, uncorrected and distance-corrected visual acuity at different distances, contrast sensitivity, aberrations and IOL decentration were measured three months after surgery. Spectacle independence, adverse photic phenomena, overall satisfaction and life quality were assessed with a questionnaire.

NCT ID: NCT05431803 Not yet recruiting - Acromegaly Clinical Trials

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

Start date: June 30, 2022
Phase:
Study type: Observational

This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly.

NCT ID: NCT05431764 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Start date: June 20, 2022
Phase: Phase 2
Study type: Interventional

In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local regional lesion, SBRT for distant metastasis) and PD-1 inhibitor long-term maintenance regimen. To investigate the efficacy and safety of "whole target" radiotherapy combined with immuno-maintenance therapy.

NCT ID: NCT05431621 Recruiting - Colorectal Cancer Clinical Trials

Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Start date: November 15, 2020
Phase:
Study type: Observational

This is a single blind, case control, multicenter study jointly developed by Zhongshan Hospital of Fudan University, Shanghai Public Health Clinical Center, Shanghai Xuhui Central Hospital, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, and Shanghai Singlera Genomics Company. The enrolled population will include positive group, precancerous lesions and healthy control group, which is expected to enroll 2,430 participants. The primary objective is to establish molecular testing methods for non-invasive screening and early diagnosis of digestive system cancers through ctDNA methylation and mutation, cfDNA and ctDNA fragment size, and end motif based model (for esophageal, gastric, colorectal cancer), and through ctDNA methylation detection, ctDNA low-pass WGS, miRNA7 and CTC detection and analysis technology based model (for hepatocellular carcinoma). The sensitivity and specificity of the models in cancer early detection will be evaluated.

NCT ID: NCT05431517 Not yet recruiting - Pancreatic Stenting Clinical Trials

Incidence, Risk Factors and Endoscopic Retrieval of Proximally Migrated Pancreatic Stents

Start date: June 2022
Phase:
Study type: Observational

This study intends to determine the incidence, risk factors and endoscopic treatment of proximally migrated pancreatic stents.

NCT ID: NCT05431504 Not yet recruiting - Clinical trials for Advanced Breast Cancer

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, single-arm, open-label, Simon's two-stage exploratory clinical trial. 18 eligible patients with advanced breast cancer with visceral crisis will enroll in stage I. If the study enter stage 2 and continue to include 53 assessable subjects (35 in stage 2). All eligible patients will receive Dalpiciclib plus endocrine therapy chosen by the Physicians until disease progression, death or intolerable toxicity. Tumor assessment was conducted according to RECIST 1.1 criteria.

NCT ID: NCT05431413 Recruiting - Depression Clinical Trials

Rapid Improvement of Depression of Fluoxetine Combined With ATP or Phosphocreatine

Start date: July 7, 2020
Phase: Phase 2
Study type: Interventional

The clinical study is a randomized (2:1), double-blind, placebo-controlled clinical study. Recruit patients with moderate to severe depression. After signing the informed consent, patients who meet the inclusion criteria will be randomly assigned to the experimental group (fluoxetine combined with ATP or phosphocreatine) and the control group (fluoxetine combined with 0.9% sodium chloride) to received treatment. Then accessed HAMD-24, HAMA, and PHQ-9 before treatment and at one, two, and four weeks after treatment to initially explore the safety and efficacy of ATP and phosphocreatine combined with fluoxetine to rapidly improves moderate to severe depression.

NCT ID: NCT05431400 Recruiting - Clinical trials for Cardiovascular Diseases

Reduction of Risk for Cardiovascular Diseases

Start date: January 1, 2020
Phase:
Study type: Observational

To establish and evaluate a new prediction model for assessing cardiovascular disease risk in community-dwelling adults.

NCT ID: NCT05431075 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Start date: July 2022
Phase: Phase 4
Study type: Interventional

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

NCT ID: NCT05431010 Not yet recruiting - Sarcopenia Clinical Trials

Efficacy on Walking Ability of Electroacupuncture Therapy in Elderly Patients With Sarcopenia

Start date: June 20, 2022
Phase: N/A
Study type: Interventional

Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia. Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial. Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.